Clinical Trials Browser

Recruiting × Lymphoma, Follicular × polatuzumab vedotin × Clear all

NCT06453044 2025-09-24

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular